Titre : Uridine diphosphate

Uridine diphosphate : Questions médicales fréquentes

Termes MeSH sélectionnés :

Limit of Detection
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate : Questions médicales les plus fréquentes", "headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-22", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Uridine diphosphate" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Nucléotides uridyliques", "url": "https://questionsmedicales.fr/mesh/D014500", "about": { "@type": "MedicalCondition", "name": "Nucléotides uridyliques", "code": { "@type": "MedicalCode", "code": "D014500", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate ose", "alternateName": "Uridine Diphosphate Sugars", "url": "https://questionsmedicales.fr/mesh/D014539", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate ose", "code": { "@type": "MedicalCode", "code": "D014539", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Uridine diphosphate N-acétylgalactosamine", "alternateName": "Uridine Diphosphate N-Acetylgalactosamine", "url": "https://questionsmedicales.fr/mesh/D014536", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate N-acétylgalactosamine", "code": { "@type": "MedicalCode", "code": "D014536", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.100" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate N-acétylglucosamine", "alternateName": "Uridine Diphosphate N-Acetylglucosamine", "url": "https://questionsmedicales.fr/mesh/D014537", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate N-acétylglucosamine", "code": { "@type": "MedicalCode", "code": "D014537", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.120" } } }, { "@type": "MedicalWebPage", "name": "Acide uridine diphosphate N-acétylmuramique", "alternateName": "Uridine Diphosphate N-Acetylmuramic Acid", "url": "https://questionsmedicales.fr/mesh/D014538", "about": { "@type": "MedicalCondition", "name": "Acide uridine diphosphate N-acétylmuramique", "code": { "@type": "MedicalCode", "code": "D014538", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.150" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate galactose", "alternateName": "Uridine Diphosphate Galactose", "url": "https://questionsmedicales.fr/mesh/D014531", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate galactose", "code": { "@type": "MedicalCode", "code": "D014531", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.300" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate glucose", "alternateName": "Uridine Diphosphate Glucose", "url": "https://questionsmedicales.fr/mesh/D014532", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate glucose", "code": { "@type": "MedicalCode", "code": "D014532", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.350" } } }, { "@type": "MedicalWebPage", "name": "Acide uridine diphosphate glucuronique", "alternateName": "Uridine Diphosphate Glucuronic Acid", "url": "https://questionsmedicales.fr/mesh/D014535", "about": { "@type": "MedicalCondition", "name": "Acide uridine diphosphate glucuronique", "code": { "@type": "MedicalCode", "code": "D014535", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.375" } } }, { "@type": "MedicalWebPage", "name": "Uridine diphosphate xylose", "alternateName": "Uridine Diphosphate Xylose", "url": "https://questionsmedicales.fr/mesh/D014540", "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate xylose", "code": { "@type": "MedicalCode", "code": "D014540", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.695.827.919.600.677.800" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Uridine diphosphate", "alternateName": "Uridine Diphosphate", "code": { "@type": "MedicalCode", "code": "D014530", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Takayuki Matsumoto", "url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp." } }, { "@type": "Person", "name": "Kumiko Taguchi", "url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan." } }, { "@type": "Person", "name": "Tsuneo Kobayashi", "url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp." } }, { "@type": "Person", "name": "Rafal Jonczyk", "url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk", "affiliation": { "@type": "Organization", "name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany." } }, { "@type": "Person", "name": "Thomas Hoffmann", "url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann", "affiliation": { "@type": "Organization", "name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Exploring the Reported Strengths and Limitations of Aboriginal and Torres Strait Islander Health Research: A Narrative Review of Intervention Studies.", "datePublished": "2023-02-23", "url": "https://questionsmedicales.fr/article/36901001", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph20053993" } }, { "@type": "ScholarlyArticle", "name": "Effect of expiratory flow limitation on ventilation/perfusion mismatch and perioperative lung function during pneumoperitoneum and Trendelenburg position.", "datePublished": "2023-02-07", "url": "https://questionsmedicales.fr/article/36748283", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.23736/S0375-9393.22.17006-9" } }, { "@type": "ScholarlyArticle", "name": "A detailed evaluation of the advantages and limitations of online RP-LC×HILIC compared to HILIC×RP-LC for phenolic analysis.", "datePublished": "2023-02-04", "url": "https://questionsmedicales.fr/article/36780845", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.chroma.2023.463843" } }, { "@type": "ScholarlyArticle", "name": "Limited dissolved oxygen facilitated nitrogen removal at biocathode during the hydrogenotrophic denitrification process using bioelectrochemical system.", "datePublished": "2023-01-21", "url": "https://questionsmedicales.fr/article/36693505", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biortech.2023.128662" } }, { "@type": "ScholarlyArticle", "name": "Preoperative Embolization of Metastatic Spinal Cord Compression with n-Butyl Cyanoacrylate: Safety and Effectiveness in Limiting Blood Loss.", "datePublished": "2023-01-14", "url": "https://questionsmedicales.fr/article/36649805", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jvir.2023.01.009" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides nucléiques, nucléotides et nucléosides", "item": "https://questionsmedicales.fr/mesh/D009706" }, { "@type": "ListItem", "position": 3, "name": "Nucléotides", "item": "https://questionsmedicales.fr/mesh/D009711" }, { "@type": "ListItem", "position": 4, "name": "Ribonucléotides", "item": "https://questionsmedicales.fr/mesh/D012265" }, { "@type": "ListItem", "position": 5, "name": "Nucléotides uridyliques", "item": "https://questionsmedicales.fr/mesh/D014500" }, { "@type": "ListItem", "position": 6, "name": "Uridine diphosphate", "item": "https://questionsmedicales.fr/mesh/D014530" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Uridine diphosphate - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Uridine diphosphate", "description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Limit+of+Detection&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Uridine diphosphate", "description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Limit+of+Detection&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Uridine diphosphate", "description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Limit+of+Detection&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Uridine diphosphate", "description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Limit+of+Detection&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Uridine diphosphate", "description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Limit+of+Detection&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Uridine diphosphate", "description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?", "url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Limit+of+Detection&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une carence en UDP ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'UDP ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP." } }, { "@type": "Question", "name": "L'UDP peut-il être mesuré dans le sang ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème d'UDP ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une carence en UDP ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs." } }, { "@type": "Question", "name": "L'UDP affecte-t-il le système nerveux ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs." } }, { "@type": "Question", "name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré." } }, { "@type": "Question", "name": "L'UDP influence-t-il l'humeur ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés à l'UDP ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes." } }, { "@type": "Question", "name": "Comment prévenir une carence en UDP ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence." } }, { "@type": "Question", "name": "Les suppléments sont-ils nécessaires pour l'UDP ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque pour l'UDP ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles l'UDP ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP." } }, { "@type": "Question", "name": "Des conseils nutritionnels existent-ils pour l'UDP ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté." } }, { "@type": "Question", "name": "Comment traiter une carence en UDP ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à l'UDP ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives pour l'UDP ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études." } }, { "@type": "Question", "name": "Les changements alimentaires sont-ils efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP." } }, { "@type": "Question", "name": "Des traitements spécifiques existent-ils pour l'UDP ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une carence en UDP ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées." } }, { "@type": "Question", "name": "L'UDP peut-il affecter le développement ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants." } }, { "@type": "Question", "name": "Des maladies chroniques sont-elles liées à l'UDP ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP." } }, { "@type": "Question", "name": "L'UDP est-il impliqué dans des maladies héréditaires ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP." } }, { "@type": "Question", "name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'UDP ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'UDP ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence." } }, { "@type": "Question", "name": "Le stress peut-il affecter l'UDP ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences." } }, { "@type": "Question", "name": "Les maladies génétiques influencent-elles l'UDP ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP." } }, { "@type": "Question", "name": "Les habitudes alimentaires jouent-elles un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP." } } ] } ] }

Sources (10000 au total)

Exploring the Reported Strengths and Limitations of Aboriginal and Torres Strait Islander Health Research: A Narrative Review of Intervention Studies.

High quality intervention research is needed to inform evidence-based practice and policy for Aboriginal and Torres Strait Islander communities. We searched for studies published from 2008-2020 in the...

Effect of expiratory flow limitation on ventilation/perfusion mismatch and perioperative lung function during pneumoperitoneum and Trendelenburg position.

Laparoscopic surgery and Trendelenburg position may affect the respiratory function and alter the gas exchange. Further the reduction of the lung volumes may contribute to the development of expirator... This is a prospective study on patients undergoing elective laparoscopic gynecological surgery. We evaluated respiratory mechanics, V/Q mismatch and presence of EFL after anesthesia induction, during ... Among the 66 patients enrolled, 25/66 (38%) exhibited EFL during surgery, of whom 10/66 (15%) after anesthesia induction, and the remaining 15 patients after pneumoperitoneum and Trendelenburg positio... Expiratory flow limitation is a common phenomenon during gynecological laparoscopic surgery associated with worsen gas exchange, increased V/Q mismatch and altered lung mechanics. Our study showed tha...

Preoperative Embolization of Metastatic Spinal Cord Compression with n-Butyl Cyanoacrylate: Safety and Effectiveness in Limiting Blood Loss.

To evaluate the safety and effectiveness of preoperative embolization with n-butyl cyanoacrylate (nBCA) performed for metastatic spinal cord compression (MSCC) in limiting blood loss (BL).... In this institutional review board-approved retrospective study, clinical records from 2017 to 2022 were reviewed. Twenty consecutive patients (11 men and 9 women; mean age, 65.8 years ± 10.0; range, ... A median of 2 levels were embolized per procedure (range, 1-5) but 4.9 were studied (range, 1-10). After embolization, tumor blush was reduced by a median of 87.3% (range, 50%-90%). The mean FT was 41... Preoperative embolization of tumors resected for MSCC with nBCA is a safe procedure allowing for performance of surgery with acceptable BL....

Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis.

Mycophenolate mofetil (MMF), a prodrug of the immunosuppressive agent mycophenolic acid (MPA), is difficult to administer because of the pharmacokinetic complexity of MPA. Although dosage adjustment a... Thirty-four adult Japanese patients receiving MMF for lupus nephritis were examined retrospectively. MPA pharmacokinetics were investigated, and a PPK model was developed using Phoenix® NLME™ software... In the pharmacokinetic analysis, renal function and serum albumin had significant effects on dose-normalized AUC... The present study developed the first PPK model of MPA for Japanese lupus nephritis patients. As for LSSs, a double sampling strategy at 1 and 4 h by multiple linear regression would work best; when o...

Evaluation of Limited Sampling Strategies for Bayesian Estimation of Daptomycin Area Under the Concentration-Time Curve: A Short Communication.

Increasing evidence supports daptomycin therapeutic drug monitoring. The author's reference center used to perform therapeutic drug monitoring in patients who receive high-dose daptomycin for bone and... The authors used the BestDose software to estimate the daptomycin AUC after Bayesian posterior estimation of individual pharmacokinetic (PK) parameters at steady state. The reference AUC (AUC full ) w... Data from 77 patients were analyzed. The mean AUC full value was 936 ± 373 mg·h/L. The best 2-sample strategy was T0 + T6, with a mean prediction bias of 0.13 mg·h/L and absolute imprecision of 3%. Th... Bayesian estimation of daptomycin AUC based on a two-sample strategy was associated with negligible bias and imprecision compared with the author's usual three-sample strategy. The trough and peak str...

Proteome-wide structural changes measured with limited proteolysis-mass spectrometry: an advanced protocol for high-throughput applications.

Proteins regulate biological processes by changing their structure or abundance to accomplish a specific function. In response to a perturbation, protein structure may be altered by various molecular ...